公开(公告)号：US20200330450A1

公开(公告)日：2020-10-22

申请号：US16905307

申请日：2020-06-18

Applicant: Exelixis, Inc.

Inventor： David Smith ,  Maha Hussain

IPC: A61K31/47 ,  A61K31/517 ,  A61K31/00 ,  C07C55/02 ,  C07D215/22

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

公开(公告)号：US11969419B2

公开(公告)日：2024-04-30

申请号：US18112214

申请日：2023-02-21

Applicant: Exelixis, Inc.

Inventor： David Smith ,  Maha Hussain

IPC: A61K31/47 ,  A61K31/00 ,  A61K31/517 ,  C07C55/02 ,  C07D215/22

CPC classification number: A61K31/47 ,  A61K31/00 ,  A61K31/517 ,  C07C55/02 ,  C07D215/22

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

公开(公告)号：US20160220554A1

公开(公告)日：2016-08-04

申请号：US14843480

申请日：2015-09-02

Applicant: Exelixis, Inc.

Inventor： David C. Smith ,  Maha Hussain

IPC: A61K31/47

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

Abstract translation: 本发明涉及用MET和VEGF的双重抑制剂治疗癌症，特别是去势抗性前列腺癌和成骨细胞骨转移瘤。

公开(公告)号：US20240156803A1

公开(公告)日：2024-05-16

申请号：US18423824

申请日：2024-01-26

Applicant: Exelixis, Inc.

Inventor： David Smith ,  Maha Hussain

IPC: A61K31/47 ,  A61K31/00 ,  A61K31/517 ,  C07C55/02 ,  C07D215/22

CPC classification number: A61K31/47 ,  A61K31/00 ,  A61K31/517 ,  C07C55/02 ,  C07D215/22

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

公开(公告)号：US20230301980A1

公开(公告)日：2023-09-28

申请号：US18112214

申请日：2023-02-21

Applicant: Exelixis, Inc.

Inventor： David Smith ,  Maha Hussain

IPC: A61K31/47 ,  A61K31/517 ,  A61K31/00 ,  C07C55/02 ,  C07D215/22

CPC classification number: A61K31/47 ,  A61K31/517 ,  A61K31/00 ,  C07C55/02 ,  C07D215/22

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

公开(公告)号：US11612597B2

公开(公告)日：2023-03-28

申请号：US16905307

申请日：2020-06-18

Applicant: Exelixis, Inc.

Inventor： David Smith ,  Maha Hussain

IPC: A61K31/47 ,  A61K31/00 ,  A61K31/517 ,  C07C55/02 ,  C07D215/22

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

公开(公告)号：US20140057908A1

公开(公告)日：2014-02-27

申请号：US13876306

申请日：2011-09-26

Applicant: Exelixis, Inc.

Inventor： David C. Smith ,  Maha Hussain

IPC: C07D215/22

CPC classification number: C07D215/22 ,  A61K31/47 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.